Literature DB >> 32367475

ω-3PUFAs Improve Cognitive Impairments Through Ser133 Phosphorylation of CREB Upregulating BDNF/TrkB Signal in Schizophrenia.

Cuiping Guo1, Yi Liu1,2, Mao-Sheng Fang3, Yuanyuan Li4, Wensheng Li1, Yacoubou Abdoul Razak Mahaman1,5, Kuan Zeng1,6, Yiyuan Xia1, Dan Ke1, Rong Liu1, Jian-Zhi Wang1,7, Hui Shen4, Xiji Shu8, Xiaochuan Wang9,10.   

Abstract

Schizophrenia (SZ) is a serious mental condition and is associated with cognitive impairments. Brain-derived neurotrophic factor (BDNF) is one of the learning- and memory-related molecules found in the CNS and its level was reported to be reduced in SZ brain, while ω-3 polyunsaturated fatty acids (ω-3PUFAs) could improve SZ symptoms, but its mechanism of action remains unknown. Using MK801 injection-induced SZ rat model, we here found that supplementation with ω-3PUFAs improved the levels of p-CREB, BDNF, and p-TrkB in the brain of SZ rats, and restore hippocampal neuronal damage, thereby reducing cognitive impairments in SZ rats. However, overexpression of AAV9/CREB S133A (CREB inactivated mutation) downregulated BDNF/TrkB signaling pathway and remarkably abolished the preventive effect of ω-3PUFAs in MK801-induced schizophrenia. Interestingly, AAV9/CREB S133D (CREB activated mutation) improved synaptic dysfunctions and cognitive defects in MK801 rats. In conclusion, these findings indicate that MK801-induced SZ lesions dephosphorylate CREB at Ser133 site, leading to neuron damage, and ω-3PUFAs improve SZ cognitive impairments by upregulating the CREB/BDNF/TrkB pathway, which provides new clues for the mechanism of SZ cognitive impairments, and a basis for therapeutic intervention.

Entities:  

Keywords:  CREB/BDNF/TrkB pathway; MK801; Schizophrenia; cognitive impairments; ω-3 polyunsaturated fatty acids

Year:  2020        PMID: 32367475      PMCID: PMC7609637          DOI: 10.1007/s13311-020-00859-w

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  38 in total

Review 1.  Potential therapeutic uses of BDNF in neurological and psychiatric disorders.

Authors:  Alan H Nagahara; Mark H Tuszynski
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

2.  Youth-focused group mindfulness-based intervention in individuals with early psychosis: A randomized pilot feasibility study.

Authors:  Arlene G MacDougall; Elizabeth Price; Matthew R J Vandermeer; Chantelle Lloyd; Richelle Bird; Rickinder Sethi; Aturan Shanmugalingam; Jason Carr; Kelly K Anderson; Ross M G Norman
Journal:  Early Interv Psychiatry       Date:  2018-10-15       Impact factor: 2.732

Review 3.  BDNF in schizophrenia, depression and corresponding animal models.

Authors:  F Angelucci; S Brenè; A A Mathé
Journal:  Mol Psychiatry       Date:  2005-04       Impact factor: 15.992

4.  Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients.

Authors:  M Takahashi; O Shirakawa; K Toyooka; N Kitamura; T Hashimoto; K Maeda; S Koizumi; K Wakabayashi; H Takahashi; T Someya; H Nawa
Journal:  Mol Psychiatry       Date:  2000-05       Impact factor: 15.992

5.  Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients.

Authors:  E N Rizos; M Papathanasiou; P G Michalopoulou; A Mazioti; A Douzenis; A Kastania; P Nikolaidou; E Laskos; K Vasilopoulou; L Lykouras
Journal:  Schizophr Res       Date:  2011-04-05       Impact factor: 4.939

6.  Examining the durability of a hybrid, remote and computer-based cognitive remediation intervention for adolescents with 22q11.2 deletion syndrome.

Authors:  Margaret A Mariano; Kerri Tang; Matthew Kurtz; Wendy R Kates
Journal:  Early Interv Psychiatry       Date:  2016-09-15       Impact factor: 2.732

Review 7.  BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.

Authors:  Bai Lu; Guhan Nagappan; Xiaoming Guan; Pradeep J Nathan; Paul Wren
Journal:  Nat Rev Neurosci       Date:  2013-05-15       Impact factor: 34.870

Review 8.  TrkB signalling pathways in LTP and learning.

Authors:  Liliana Minichiello
Journal:  Nat Rev Neurosci       Date:  2009-12       Impact factor: 34.870

9.  Transcriptome alterations of prefrontal cortical parvalbumin neurons in schizophrenia.

Authors:  J F Enwright Iii; Z Huo; D Arion; J P Corradi; G Tseng; D A Lewis
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

Review 10.  Memory and cognition in schizophrenia.

Authors:  J Y Guo; J D Ragland; C S Carter
Journal:  Mol Psychiatry       Date:  2018-09-21       Impact factor: 15.992

View more
  8 in total

1.  Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects.

Authors:  Jiali Chen; Guangying Li; Pingping Qin; Jiaojiao Chen; Na Ye; John L Waddington; Xuechu Zhen
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

2.  PTMs: A Missing Piece for Schizophrenia Studies.

Authors:  Caroline Brandão-Teles; Bradley J Smith; Victor Corasolla Carregari
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  Metformin attenuates LPS-induced neuronal injury and cognitive impairments by blocking NF-κB pathway.

Authors:  Chenliang Zhou; Bo Peng; Zhenghui Qin; Wei Zhu; Cuiping Guo
Journal:  BMC Neurosci       Date:  2021-11-26       Impact factor: 3.288

4.  USP10 deubiquitinates Tau, mediating its aggregation.

Authors:  Zhen Wei; Kuan Zeng; Jichang Hu; Xing Li; Fang Huang; Bin Zhang; Jian-Zhi Wang; Rong Liu; Hong-Lian Li; Xiaochuan Wang
Journal:  Cell Death Dis       Date:  2022-08-20       Impact factor: 9.685

5.  Selenium Nanoparticles-Enriched Lactobacillus casei ATCC 393 Prevents Cognitive Dysfunction in Mice Through Modulating Microbiota-Gut-Brain Axis.

Authors:  Lei Qiao; Yue Chen; Xiaofan Song; Xina Dou; Chunlan Xu
Journal:  Int J Nanomedicine       Date:  2022-10-13

Review 6.  The effects and mechanism of environmental enrichment on MK-801 induced cognitive impairment in rodents with schizophrenia.

Authors:  Jinwei Xu; Yaohao Li; Biqing Tian; Haiying Liu; Shengxi Wu; Wenting Wang
Journal:  Front Cell Neurosci       Date:  2022-09-29       Impact factor: 6.147

Review 7.  BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review.

Authors:  Rodrigo R Nieto; Andrea Carrasco; Sebastian Corral; Rolando Castillo; Pablo A Gaspar; M Leonor Bustamante; Hernan Silva
Journal:  Front Psychiatry       Date:  2021-06-16       Impact factor: 4.157

8.  The effect of propofol on hypoxia- and TNF-α-mediated BDNF/TrkB pathway dysregulation in primary rat hippocampal neurons.

Authors:  Weiping Tao; Xuesong Zhang; Juan Ding; Shijian Yu; Peiqing Ge; Jingfeng Han; Xing Luo; Wei Cui; Jiawei Chen
Journal:  CNS Neurosci Ther       Date:  2022-02-03       Impact factor: 5.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.